Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

Lotte Marieke Knapen; Rutger H. T. Koornstra; Johanna H. M. Driessen; Bas Van Vlijmen; Sander Croes; Stein J. Schalkwijk; Angela Colbers; Winald Gerritsen; David Burger; Frank de Vries; Nielka P. Van Erp

doi:10.1200/JCO.2017.35.15_suppl.9540

Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

Lotte Marieke Knapen
, Rutger H. T. Koornstra
, Johanna H. M. Driessen
, Bas Van Vlijmen
, Sander Croes
, Stein J. Schalkwijk
, Angela Colbers
, Winald Gerritsen
, David Burger
, Frank de Vries
, Nielka P. Van Erp

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	Journal of Clinical Oncology
Volume	35
DOIs	https://doi.org/10.1200/JCO.2017.35.15_suppl.9540
Publication status	Published - 20 May 2017

Access to Document

10.1200/JCO.2017.35.15_suppl.9540

Cite this

Knapen, L. M., Koornstra, R. H. T., Driessen, J. H. M., Van Vlijmen, B., Croes, S., Schalkwijk, S. J., Colbers, A., Gerritsen, W., Burger, D., de Vries, F., & Van Erp, N. P. (2017). Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study. Journal of Clinical Oncology, 35. https://doi.org/10.1200/JCO.2017.35.15_suppl.9540

@article{0d87dbf936e5412ba590c57f1ca8f76b,

title = "Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.",

author = "Knapen, \{Lotte Marieke\} and Koornstra, \{Rutger H. T.\} and Driessen, \{Johanna H. M.\} and \{Van Vlijmen\}, Bas and Sander Croes and Schalkwijk, \{Stein J.\} and Angela Colbers and Winald Gerritsen and David Burger and \{de Vries\}, Frank and \{Van Erp\}, \{Nielka P.\}",

year = "2017",

month = may,

day = "20",

doi = "10.1200/JCO.2017.35.15\_suppl.9540",

language = "English",

volume = "35",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

}

Knapen, LM, Koornstra, RHT, Driessen, JHM, Van Vlijmen, B, Croes, S, Schalkwijk, SJ, Colbers, A, Gerritsen, W, Burger, D, de Vries, F & Van Erp, NP 2017, 'Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.', Journal of Clinical Oncology, vol. 35. https://doi.org/10.1200/JCO.2017.35.15_suppl.9540

Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study. / Knapen, Lotte Marieke; Koornstra, Rutger H. T.; Driessen, Johanna H. M. et al.
In: Journal of Clinical Oncology, Vol. 35, 20.05.2017.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

AU - Knapen, Lotte Marieke

AU - Koornstra, Rutger H. T.

AU - Driessen, Johanna H. M.

AU - Van Vlijmen, Bas

AU - Croes, Sander

AU - Schalkwijk, Stein J.

AU - Colbers, Angela

AU - Gerritsen, Winald

AU - Burger, David

AU - de Vries, Frank

AU - Van Erp, Nielka P.

PY - 2017/5/20

Y1 - 2017/5/20

U2 - 10.1200/JCO.2017.35.15_suppl.9540

DO - 10.1200/JCO.2017.35.15_suppl.9540

M3 - Meeting Abstract

SN - 0732-183X

VL - 35

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Knapen LM, Koornstra RHT, Driessen JHM, Van Vlijmen B, Croes S, Schalkwijk SJ et al. Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study. Journal of Clinical Oncology. 2017 May 20;35. doi: 10.1200/JCO.2017.35.15_suppl.9540